Alexandria Hammond
Stock Analyst at Wolfe Research
(2.74)
# 1,815
Out of 5,241 analysts
16
Total ratings
80%
Success rate
13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterates: Outperform | $1,325 | $988.09 | +34.10% | 2 | May 4, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $522.23 | +1.30% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $209.41 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $112.56 | +19.94% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $629.68 | +82.63% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.33 | -1.30% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $48.11 | -16.86% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $228.92 | -17.00% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $129.67 | -15.17% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $57.31 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $191.91 | - | 1 | Nov 15, 2024 |
Eli Lilly and Company
May 4, 2026
Reiterates: Outperform
Price Target: $1,325
Current: $988.09
Upside: +34.10%
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $522.23
Upside: +1.30%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $209.41
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $112.56
Upside: +19.94%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $629.68
Upside: +82.63%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.33
Upside: -1.30%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $48.11
Upside: -16.86%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $228.92
Upside: -17.00%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $129.67
Upside: -15.17%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.31
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $191.91
Upside: -